Global pharmaceutical corporations are accelerating investments in domestic and regional biomanufacturing facilities. Recent geopolitical supply disruptions have highlighted critical vulnerabilities in the procurement of Active Pharmaceutical Ingredients.
Capital Expenditure Allocation
Major drugmakers are deploying capital toward continuous manufacturing technologies and modular automated cleanrooms. Regulatory agencies are providing expedited approval pathways for facilities adopting advanced manufacturing technologies to secure critical medicine stockpiles.